Los incentivos en favor de los medicamentos huérfanos

Jordi Faus

CUADERNOS DE DERECHO FARMACÉUTICO, NUMBER. 72, JANUARY-MARCH 2020

Since 2016, the European Union is considering whether it is necessary or not to review the incentives that EU pharmaceutical legislation contemplates in connection with the research and development of orphan drugs. This article explains which are the current incentives, and which are the main ideas that are currently on the table in connection with such review. The author concludes recommending prudence in the review of a system which has proven to be efficient as regards the achievement of the objectives for which it was designed.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información. ACEPTAR

Aviso de cookies